Cellectis S.A.

ALCLS

FR0010425595

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 10:20:45 2026-05-21 am EDT			5-day change	1st Jan Change
3.048 ^EUR	-4.21%		-14.62%	-27.34%

May. 19	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT
May. 15	European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading	MT

European Equities Traded in the US as American Depositary Receipts Advance Wednesday

Published on 06/04/2025 at 11:19 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cellectis S.A.

May. 19	European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	MT
May. 15	European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading	MT
May. 14	European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading	MT
May. 12	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading	MT
May. 12	Cellectis S.A. Presents Clinical Data On Lasme-Cel And Eti-Cel At Eha 2026 Annual Congress	CI
May. 12	Atos, Fnac Darty, Chargeurs... stocks to watch today in Paris
May. 12	Cellectis extends cash runway into Q4 2027
May. 11	Cellectis S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 11	European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading	MT
May. 11	Weekly Earnings Calendar
May. 06	European Equities Traded in the US as American Depositary Receipts Climb Sharply Higher in Wednesday Trading	MT
May. 05	It's kicking off, but they're still talking
May. 04	European Equities Traded in the US as American Depositary Receipts Start Week Lower	MT
May. 01	European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week	MT
Apr. 29	European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading	MT

Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR T cells for the treatment of cancer patients, and a platform for for the development of gene therapies in other therapeutic indications. Thanks to its fully in-house production capabilities, Cellectis S.A. is one of the few genome-editing companies to control the cell and gene therapy value chain from end to end.

Employees

227

Sector

Biotechnology & Medical Research

More about the company